8-K: Tandem Diabetes Care Exceeds $1B Sales, Guides 2026 Growth

Tandem Diabetes Care reported record Q4 2025 sales and surpassed $1 billion in full-year worldwide sales, while providing 2026 financial guidance.

Summary

• Achieved record quarterly worldwide sales of $290.4 million in Q4 2025, with United States sales at $210.5 million and worldwide pump shipments of 38,000.
• Delivered record quarterly gross margin of 58% and operating income of $8.3 million (3% of sales) in Q4 2025.
• Reported a net loss of $0.6 million but positive adjusted EBITDA of $32.9 million (11% of sales) and positive free cash flow of $3.1 million in Q4 2025.
• Achieved a milestone of $1.015 billion in worldwide sales for the full year 2025, with over 126,000 worldwide pump shipments and an expanded gross margin of 54%.
• Began global commercial rollout of t:slim X2 pump integration with the FreeStyle Libre 3 Plus continuous glucose monitoring sensor.
• Initiated the launch of Android mobile control for the Tandem Mobi insulin delivery system.
• Introduced a pay-as-you-go pharmacy structure in the United States and began direct commercial operations in select European countries.
• Filed a 510(k) with the FDA for a pregnancy indication for Control-IQ+ technology.
• Provided 2026 full year sales guidance of approximately $1.065 billion to $1.085 billion, with US sales estimated at $730 million to $745 million (reflecting a $70 million to $80 million pay-as-you-go headwind).
• Projected 2026 international sales of approximately $335 million to $340 million (reflecting a $15 million direct transition headwind).
• Estimated 2026 gross margin to be approximately 56% to 57% of sales and adjusted EBITDA margin to be approximately 5% to 6% of sales.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, highlighting strong Q4 operational improvements and a significant full-year sales milestone, alongside strategic initiatives for future growth despite anticipated short-term headwinds from business model transitions.

Positives

• Record quarterly worldwide sales of $290.4 million in Q4 2025, representing a 15% Non-GAAP increase year-over-year.
• Achieved a significant milestone of $1.015 billion in worldwide sales for the full year 2025.
• Record quarterly gross margin of 58% in Q4 2025, up from 51% Non-GAAP in Q4 2024.
• Positive GAAP operating income of $8.3 million (3% of sales) in Q4 2025, a substantial improvement from an operating loss of $0.6 million in Q4 2024.
• Adjusted EBITDA significantly improved to $32.9 million (11% of sales) in Q4 2025, compared to $2.3 million (1% of sales) in Q4 2024.
• Generated positive cash flow from operating activities of $9.8 million and positive free cash flow of $3.1 million in Q4 2025.
• Expanded full year 2025 GAAP gross margin to 54% from 52% in 2024.
• Successfully began global commercial rollout of t:slim X2 pump integration with the FreeStyle Libre 3 Plus CGM sensor.
• Initiated the launch of Android mobile control for the Tandem Mobi insulin delivery system, enhancing product portfolio.
• Strategic introduction of a pay-as-you-go pharmacy structure in the US and direct commercial operations in select European countries are expected to drive future growth.
• Filed a 510(k) with the FDA for a pregnancy indication for Control-IQ+ technology, expanding potential market segments.
• Projected double-digit pump shipment growth for 2026, indicating continued market expansion.
• Management anticipates accelerated sales growth in 2027 and beyond, following strategic transitions.

Negatives

• GAAP net loss of $0.6 million in Q4 2025, compared to a net income of $0.8 million in Q4 2024.
• Full year 2025 GAAP operating loss increased to $187.3 million (negative 18% of sales) from $99.1 million (negative 11% of sales) in 2024.
• Full year 2025 GAAP net loss widened to $204.7 million from $96.0 million in 2024.
• Full year 2025 Adjusted EBITDA was negative $46.1 million (negative 5% of sales), including a $75.2 million negative impact from an acquired in-process research and development charge.
• Full year 2025 GAAP cash used in operating activities was $9.7 million, a reversal from $24.2 million provided in 2024.
• Full year 2025 Non-GAAP free cash flow was negative $29.7 million, compared to positive $5.0 million in 2024.
• 2026 sales expectations include a pay-as-you-go headwind of approximately $70 million to $80 million in the US, which may obscure immediate revenue growth.
• 2026 international sales guidance includes a direct transition headwind of approximately $15 million.
• Cash, cash equivalents and short-term investments decreased from $438.3 million at December 31, 2024, to $292.7 million at December 31, 2025.
• Total assets decreased from $967.7 million at December 31, 2024, to $881.1 million at December 31, 2025.

Risks

• Market acceptance of the company's products.
• Competition from products marketed and sold or under development by competitors.
• Ability to establish and sustain operations to support international sales, including expanding into additional geographies.
• Changes in reimbursement rates or insurance coverage for the company's products.
• Ability to meet increasing operational and infrastructure requirements from higher customer interest and a larger base of existing customers.
• Ability to successfully commercialize its products.
• Ability to develop and launch new products.
• Risks associated with the regulatory approval process internationally for new products.
• Potential that newer products, or other technological breakthroughs for the monitoring, treatment or prevention of diabetes, may render the company's products obsolete or less desirable, or may otherwise negatively impact the purchasing trends of customers.
• Reliance on third-party relationships, such as outsourcing and supplier arrangements.
• Global economic conditions.
• Other risks identified in the company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

Future Outlook

Tandem Diabetes Care projects worldwide sales of $1.065 billion to $1.085 billion for 2026, with US shipments expected to grow 10% to 11%. The company anticipates a gross margin of 56% to 57% and an adjusted EBITDA margin of 5% to 6%. Management expects the transition to a pay-as-you-go model in the US and direct international operations to create headwinds in 2026 but position the company for accelerated sales growth in 2027 and beyond.

Management Comments

• "2025 was a defining year for Tandem as we surpassed $1 billion in worldwide sales and set gross margin records, while modernizing our commercial operations, reshaping our business model, and driving innovation." John Sheridan, President and CEO.
• "In 2026, we plan to build upon this momentum as we further strengthen our business, while delivering new technology solutions to improve the lives of people with diabetes." John Sheridan, President and CEO.
• "In 2026, our goal is to expand the worldwide market by delivering double-digit pump shipment growth. We are adopting a pay-as-you-go model in the U.S. that provides affordable access to customers, and progresses our business toward more predictable and profitable revenue that may not be evident in our 2026 sales expectations." Leigh Vosseller, Executive Vice President and CFO.
• "We remain committed to improving margins and profitability during this transition that positions Tandem for accelerated sales growth in 2027 and beyond." Leigh Vosseller, Executive Vice President and CFO.

Industry Context

StockSavvy.ai notes that Tandem Diabetes Care's strategic shift to a pay-as-you-go model and direct international operations reflects a broader industry trend towards more flexible patient access and localized market penetration. The focus on integrating with leading CGM sensors like FreeStyle Libre 3 Plus and expanding mobile control capabilities is crucial for remaining competitive in the rapidly evolving diabetes technology landscape, where user convenience and interoperability are key differentiators against rivals like Insulet (Omnipod) and Medtronic.

Stakeholder Impact

• Shareholders: Potential for increased long-term value through strategic business model changes and anticipated accelerated sales growth post-2026, though short-term headwinds from transitions may impact immediate profitability.
• Customers: Improved access to insulin delivery systems through the new pay-as-you-go pharmacy structure and enhanced product offerings like FreeStyle Libre 3 Plus integration and Android mobile control.
• Employees: Continued focus on innovation and global expansion could lead to new opportunities, but the relocation of certain research and development activities (as noted in financial footnotes) may involve internal restructuring.
• Healthcare Providers: New technology integrations and expanded commercial operations could offer more advanced tools for diabetes management.

Next Steps

• Build upon 2025 momentum in 2026.
• Further strengthen the business in 2026.
• Deliver new technology solutions to improve the lives of people with diabetes in 2026.
• Expand the worldwide market by delivering double-digit pump shipment growth in 2026.
• Improve margins and profitability during the transition to new business models.
• Position Tandem for accelerated sales growth in 2027 and beyond.
• Continue the transition to a pay-as-you-go business model in the US pharmacy channel.
• Prepare for the transition to direct commercial operations in select international countries.

Key Dates

Recommendation

The company demonstrated strong operational improvements in Q4 2025, achieving record gross margins and positive operating income and cash flow. Surpassing $1 billion in annual sales is a significant milestone. While 2026 guidance includes anticipated headwinds from strategic business model transitions (pay-as-you-go and direct international operations), these initiatives are expected to position Tandem for accelerated sales growth and more predictable, profitable revenue in 2027 and beyond. The continued innovation with new product integrations and regulatory filings further strengthens its market position, making it an attractive long-term investment despite short-term transition impacts.

Keywords

Diabetes Technology, Insulin Delivery, CGM Integration, Tandem Mobi, t:slim X2, Control-IQ+, Medical Devices, Financial Results, SEC Filing, Earnings, Guidance, Healthcare, Biotechnology